Page 44 - JCTR-10-1

40 Gonda et al. | Journal of Clinical and Translational Research 2024; 10(1): 33-51
Health 2021;9:705916. Myopathy Following SARS-CoV-2 Infection: A Case
doi: 10.3389/fpubh.2021.705916 Report and Review of Recent Literature. Skelet Muscle
[15] Li G, Wu X, Zhou CL, Wang YM, Song B, Cheng XB, 2021;11:10.
et al. Uric Acid as a Prognostic Factor and Critical Marker doi: 10.1186/s13395-021-00266-5
of COVID-19. Sci Rep 2021;11:17791. [27] Rey JR, Caro-Codón J, Rosillo SO, Iniesta AM,
doi: 10.1038/s41598-021-96983-4 Castrejón-Castrejón S, Marco-Clement I, et al. Heart
[16] Sacchi MC, Tamiazzo S, Stobbione P, Agatea L, De Failure in COVID-19 Patients: Prevalence, Incidence
Gaspari P, Stecca A, et al. SARS-CoV-2 Infection as and Prognostic Implications. Eur J Heart Fail 2020;22:
a Trigger of Autoimmune Response. Clin Transl Sci 2205-15.
2021;14:898-907. doi: 10.1002/ejhf.1990
doi: 10.1111/cts.12953 [28] Peghin M, De Martino M, Fabris M, Palese A, Visintini E,
[17] Noori M, Nejadghaderi SA, Sullman MJ, Carson- Graziano E, et al. The Fall in Antibody Response to
Chahhoud K, Kolahi AA, Safiri S. Epidemiology, Prognosis SARS-CoV-2: A Longitudinal Study of Asymptomatic to
and Management of Potassium Disorders in Covid-19. Rev Critically Ill Patients up to 10 Months After Recovery.
Med Virol 2022;32:e2262. J Clin Microbiol 2021;59:e0113821.
doi: 10.1002/rmv.2262 doi: 10.1128/JCM.01138-21
[18] Palladino M. Complete Blood Count Alterations in [29] Sterlin D, Mathian A, Miyara M, Mohr A, Anna F,
COVID-19 Patients: A Narrative Review. Biochem Med Claër L, et al. IgA Dominates the Early Neutralizing
(Zagreb) 2021;31:030501. Antibody Response to SARS-CoV-2. Sci Transl Med
doi: 10.11613/BM.2021.030501 2021;13:eabd2223.
[19] Luo X, Zhou W, Yan X, Guo T, Wang B, Xia H, et al. doi: 10.1126/scitranslmed.abd2223
Prognostic Value of C-Reactive Protein in Patients with [30] Jing X, Xu M, Song D, Yue T, Wang Y, Zhang P, et al.
Coronavirus 2019. Clin Infect Dis 2020;71:2174-9. Association Between Inflammatory Cytokines and anti-
doi: 10.1093/cid/ciaa641 SARS-CoV-2 Antibodies in Hospitalized Patients with
[20] Keski H. Hematological and Inflammatory Parameters COVID-19. Immun Ageing 2022;19:12.
to Predict the Prognosis in COVID-19. Indian J Hematol doi: 10.1186/s12979-022-00271-2
Blood Transfus 2021;37:534-42. [31] Gooding R, Riches P, Dadian G, Moore J, Gore M.
doi: 10.1007/s12288-021-01407-y Increased Soluble Interleukin-2 Receptor Concentration in
[21] Sarkar PG, Pant P, Kumar J, Kumar A. Does Neutrophil- Plasma Predicts a Decreased Cellular Response to IL-2. Br
to-lymphocyte Ratio at Admission Predict Severity and J Cancer 1995;72:452-5.
Mortality in COVID-19 Patients? A Systematic Review and doi: 10.1038/bjc.1995.354
Meta-analysis. Indian J Crit Care Med 2022;26:361-75. [32] Ozaki A, Sawano T, Saito H, Tanimoto T, Tsubokura M.
doi: 10.5005/jp-journals-10071-24135 Will Initial Consultation Patterns among Undiagnosed
[22] Wool GD, Miller JL. The Impact of COVID-19 Disease on Cancer Patients be the Same After this COVID-19
Platelets and Coagulation. Pathobiology 2021;88:15-27. Pandemic? Experiences from the 2011 Triple Disaster in
doi: 10.1159/000512007 Fukushima, Japan. J Glob Health 2020;10:020343.
[23] Ouyang SM, Zhu HQ, Xie YN, Zou ZS, Zuo HM, doi: 10.7189/jogh.10.020343
Rao YW, et al. Temporal Changes in Laboratory Markers [33] Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Viant C,
of Survivors and Non-survivors of Adult Inpatients with Gaebler C, et al. Enhanced SARS-CoV-2 Neutralization
COVID-19. BMC Infect Dis 2020;20:952. by Dimeric IgA. Sci Transl Med 2021;13:eabf1555.
doi: 10.1186/s12879-020-05678-0 doi: 10.1126/scitranslmed.abf1555
[24] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical [34] Santani BG, LeBlanc BW, Thakare RP. Molnupiravir
Course and Risk Factors for Mortality of Adult Inpatients for the Treatment of COVID-19. Drugs Today (Barc)
with COVID-19 in Wuhan, China: A Retrospective Cohort 2022;58:335-50.
Study. Lancet 2020;395:1054-62. doi: 10.1358/dot.2022.58.7.3419558
doi: 10.1016/S0140-6736(20)30566-3 [35] Painter GR, Natchus MG, Cohen O, Holman W, Painter WP.
[25] Dhamoon MS, Thaler A, Gururangan K, Kohli A, Developing a Direct Acting, Orally Available Antiviral
Sisniega D, Wheelwright D, et al. Acute Cerebrovascular Agent in a Pandemic: The Evolution of Molnupiravir as
Events with COVID-19 Infection. Stroke 2021;52:48-56. a Potential Treatment for COVID-19. Curr Opin Virol
doi: 10.1161/STROKEAHA.120.031668 2021;50:17-22.
[26] Islam B, Ahmed M, Islam Z, Begum SM. Severe Acute doi: 10.1016/j.coviro.2021.06.003
DOI: https://doi.org/10.36922/jctr.00075